Prohibition Partners
Home / Cannabis Markets / Ireland
Ireland flag

Is cannabis legal in Ireland?

Medical cannabis is legal in Ireland and adult-use is illegal. Below: a free market overview, with the full sizing, regulation and trade data available from PP.

Medical: LegalAdult-use: IllegalCBD covered
Compare withCyprusEstonia

Market size

Medical cannabis sales and registered patients in Ireland, 2025 actuals and the 2027 forecast. Forecasts to 2030 are in the Ireland data pack.

Medical sales, EUR

€128.9k2025€141.4k2026€153.8k2027202820292030
Metric202520262027202820292030
Medical sales€128.9k€141.4k€153.8k
Patients211232252

Forecasts to 2030 — sales, patients and the full Ireland series — are in the Ireland data pack, or scoped to your question in a bespoke brief.

See the data pack Request a brief

Source: Prohibition Partners — Global Medical Cannabis Market Review (2026, updated April 2026) & The European Cannabis Report (2025)

Recently in Ireland

From International Cannabis Weekly, our free global briefing.

Latest issue №467
  1. Ireland's cross-party drugs committee calls for full decriminalisation

    Business of Cannabis · 456 · 3 Jul 2026 · Regulation

  2. Irish medical cannabis CEO discusses innovation in a tightly controlled emerging sector

    siliconrepublic.com · 453 · 12 Jun 2026 · Business & Investment

  3. Ireland's medical cannabis programme continues to stagnate despite patient need

    Newsweed · 447 · 1 May 2026 · Medical

  4. Ireland moves forward with review of medical cannabis programme after five years

    Business of Cannabis · 444 · 10 Apr 2026 · Medical

  5. Ireland bans synthetic hemp intoxicant HHC after rising psychiatric case reports

    412 · 8 Aug 2025 · Regulation

  6. Dublin airport medication seizure highlights failures in Ireland's medical cannabis policy

    Cannabis Health · 390 · 7 Mar 2025 · Medical

Medical cannabis — overview

In 2019, Ireland launched its Medical Cannabis Access Programme (MCAP), which allowed for patients suffering from specific conditions to access medical cannabis treatment. Previously, patients had only been able to access medical cannabis under ministerial licence, granted by the Minister of Health.

Patients can currently access medical cannabis through both pathways, however in practice, few patients are receiving medical cannabis treatment. The process for ministerial licence application is long and bureaucratic, while under MCAP the pool of eligible patients is limited, restricted to those suffering from three conditions: spasticity from multiple sclerosis, nausea from chemotherapy, and neuropathic pain. In both cases, doctors specialising in a relevant condition are required to prescribe.

Patients receiving treatment under MCAP are eligible for reimbursement if they qualify for a health card (a means-tested programme for public healthcare coverage), whereas those under ministerial licence have to pay for treatment fully.

Given the lack of medical cannabis treatment, products often have to be imported on a per-prescription basis, raising costs for patients further. Under MCAP, there is a list of approved extract-based products, while under ministerial licence the only products available are Bedrocan products, transformed into extract products by a magistral pharmacy in the Netherlands.